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ABSTRACT

Objective Non-pharmacological interventions support
patients with connective tissue diseases to better cope
with and self-manage their diseases. This study aimed
to map existing evidence on non-pharmacological
interventions in patients with systemic lupus
erythematosus (SLE), systemic sclerosis (SSc) and
mixed connective tissue diseases regarding content,
feasibility and potential suitability in an e-health
setting.
►► Additional supplemental
material is published online only. Methods A literature search was performed in eight
different databases in July 2020. The intervention’s
To view, please visit the journal
online (http://dx.doi.org/10.
content was extracted using the ‘Better reporting of
1136/rmdopen-2021-001710).
interventions: template for intervention description
and replication (TIDieR) checklist and guide’. A Sankey
diagram and descriptive statistics were used to analyse
Received 21 April 2021
the data and illustrate the relationships between the
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interventions.
Results Of 8198 identified records, 119 papers were
eligible. One hundred and four of them (87.4%) were
conducted between 2000 and 2020, mainly in the
USA (SLE n=24 (21.2%), SSc n=16 (14.2%)), Brazil
(SLE n=8 (7.1%), SSc n=5 (4.4%)) and Italy (SLE n=0
(0%), SSc n=12 (10.6%)). Fifty-two studies (SLE n=24
(21.2%), SSc n=28 (24.8%)) used multicomponent
interventions. The single interventions were physical
exercises (SLE n=16 (14.2%), SSc n=17 (15.0%)),
coaching/counselling (SLE n=11 (18.0%), SSc n=0
(0%)) and education (SLE n=2 (1.8%), SSc n=3 (2.7%)).
Primary outcomes focused on physical function (SLE
n=1 (0.9%), SSc n=15 (13.3%)), mouth opening in SSc
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(n=4 (5.9%)) and physical capacity (SLE n=2 (1.8%),
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SSc n=1 (0.9%)). No interventions for mixed connective
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Conclusion There was a great variety in the
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intervention’s content due to differences in body
structure, activity limitations and participation
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restrictions in SLE and SSc. These results highlight
the need for personalised, multicomponent, non-
Correspondence to
pharmacological interventions, which could be delivered
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as e-health interventions.
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Key messages
What is already known about this subject?
►► Persons suffering from autoimmune connective

tissue diseases (CTD), such as systemic sclerosis (SSc), systemic lupus erythematosus (SLE) and
mixed connective tissue diseases (MCTD), experience limitations in physical and mental function,
activities of daily life and participation, also leading
to a reduced quality of life.

What does this study add?
►► Consistent with the people’s limitations in their daily

routines, various non-
pharmacological interventions/programmes exist for SSc and SLE. We did not
find non-pharmacological interventions for MCTD.
►► The most common interventions included patient
education, self-management, physical activity/exercise and advice regarding a healthy lifestyle.

How might this impact on clinical practice or
further developments?
►► Multicomponent, non-pharmacological interventions

in people with CTDs should be personalised to increase effectiveness.
►► Multicomponent e-
health interventions target the
different needs of patients with CTDs.
►► E-
health settings allow patients easier access to
specialised health professionals.

INTRODUCTION
Connective tissue diseases (CTDs), such
as systemic sclerosis (SSc),1 systemic lupus
erythematosus (SLE)2 and mixed connective
tissue diseases (MCTD),3 are rare chronic
autoimmune diseases of unknown aetiology
which affect several organ systems, such as the
skin, heart, lungs, kidneys, joints, muscles and
blood vessels.4 5 Consequently, people with
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CTDs experience fatigue, pain, reduced mobility/range
of motion, shortness of breath and decreased physical
function. Thus, CTDs often lead to activity limitations,
participation restrictions, psychosocial and economic
consequences and reduced health-
related quality of
life.6–10
Non-
pharmacological interventions support patients
with CTDs, to better cope with and self-manage their
diseases, thereby increasing their quality of life. Non-
pharmacological interventions are most commonly
delivered by health professionals in rheumatology,11 and
several studies have been conducted to establish their
effectiveness. For instance, recent reviews demonstrated
that being physically active and performing exercises
positively impacts fatigue in people with SSc and SLE.12–15
However, these reviews focused only on a specific type
of intervention (eg, exercises12–14) or restricted the study
designs (eg, included only randomised controlled trials
(RCTs)15). Research of interventions using other study
designs, such as case studies or qualitative studies, is
under-represented in these reviews. To date, a comprehensive overview of different non-
pharmacological
interventions is lacking. Furthermore, given the small
number of patients with SLE and SSc (1–5 individuals
per 10.000)16–18 and their particular needs, health professionals who are experts in CTDs are often not easily
accessible for these patients especially in rural areas.19 20
Consequently, telehealth interventions or remote consultations with experts have been previously suggested.21 22
Besides, the current COVID-19 pandemic has even more
increased the need for remote healthcare. However, telehealth or other remote interventions in CTDs have not
yet been explicitly covered in any of the current reviews.
To define the term e-health, we used the definition
of the WHO and the description of the term ‘telemedicine’ as defined in the Medical Subject Headings terms
by PubMed. The WHO defines e-health as the ‘use of
information and communication technologies (ICT)
for health’.23 Telemedicine is defined as the ‘Delivery
of health services via remote telecommunications’.24
Both definitions include interactive consultative and
diagnostic services and comprise terms such as ‘mobile
health’, ‘m-health’, ‘telehealth’ and ‘e-health’.
The objective of this study was to map the existing
evidence of non-
pharmacological interventions in
patients with SLE, SSc and MCTD regarding content,
feasibility and potential suitability in an e-health setting.
MATERIALS AND METHODS
We conducted a scoping review25 using the guidelines of
the Joanna Briggs Institute’s (JBI) approach to evidence-
based healthcare methodology to map and describe
the content of existing non-pharmacological interventions applicable for patients with SSc, SLE and MCTD.
In the second step, we conducted an analysis to provide
some insights of effectiveness. Our findings are reported
according to the ‘PRISMA Extension for Scoping
2

Reviews (PRISMA-
ScR): Checklist and Explanation’.26
The protocol of this scoping review was published on
researchgate.net (DOI: 10.13140/RG.2.2.22193.43363).
Search strategy
An initial search, limited to PubMed and CINAHL, was
performed (by VR, RF, EJFS) to identify the first articles
on this topic to develop a search strategy. In the second
step, this search strategy was used to conduct an adapted
and more extensive query in eight different databases:
MEDLINE (PubMed), EMBASE (OVID), CINAHL
(EBSCO), PsycINFO (ProQUEST), the Cochrane Database of Systematic Reviews, OTSeeker, PEDro and SciELO
(online supplemental file 1). Further, members of the
research group were consulted by email to identify additional grey literature or research that had not been found
through the database query. Reference lists of identified
papers were searched for any additional relevant articles
subjected to the same screening and selection process.
There were no exclusions of papers based on publication
date.
Study selection and inclusion criteria
All identified studies/articles/reports in the queries were
uploaded into EndNote and duplicates removed. The
selection process had two phases. First, two researchers
(VR, RF) independently screened the titles whether
they met inclusion/exclusion criteria or not, followed
by screening the abstracts. A third researcher (TAS)
assessed possible disparities in selecting these titles and/
or abstracts. Second, the full texts for all selected publications were retrieved and read (VR, EJ). When in doubt
whether a paper met the inclusion/exclusion criteria,
a third researcher (TAS) was asked to assess the paper
and the decision was made by consensus. According to
the PRISMA-ScR,26 reasons for the exclusion of full-text
studies are provided (online supplemental file 2). The
results of the selection are presented in a Preferred
Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) flow diagram (figure 1).
The following inclusion criteria guided the selection of
publications. Following the JBI,25 the PCC (participants,
concept and context) mnemonic and study design were
used to screen the studies.
Participants
Studies were included in this scoping review if participants in the study had a diagnosis of SSc, SLE or MCTD.
Concept
Studies were included if any non-
pharmacological,
non-
surgical intervention (such as exercises, education, psychosocial intervention, etc) was investigated
(either the development and/or the evaluation of a non-
pharmacological intervention). The intervention had
to be described in sufficient detail (at least content and
setting) to be included.
Ritschl V, et al. RMD Open 2021;7:e001710. doi:10.1136/rmdopen-2021-001710
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Figure 1

Flow chart of the search and selection process performed in September 2018 and updated in July 2020.

Context
This scoping review considered all contexts (home
care, community services, primary healthcare, hospital
settings, etc).
Types of studies
Any quantitative (experimental study/observational)
research designs and any qualitative study/design
assessing participants’ perspectives on interventions were
included. Theoretical studies were excluded.
Data extraction
Study characteristics were extracted using a data extraction form as indicated by the methodology for scoping
reviews developed by the JBI.25 The described interventions were further extracted using the ‘Better reporting
of interventions: template for intervention description
and replication (TIDieR) checklist and guide’.27 Two
reviewers (VR, EJ) extracted the data independently. Any
disagreements that arose between these reviewers were
resolved through discussion until consensus was reached.
Ritschl V, et al. RMD Open 2021;7:e001710. doi:10.1136/rmdopen-2021-001710

Assessment of risk of bias and descriptive analysis
The quality of retrieved RCTs was assessed using the ‘RoB
2: a revised tool for assessing the risk of bias in randomised
trials’28 (online supplemental file 3). Other study designs
were used to extract information on the intervention’s
content but not analysed further regarding risk of bias.
Due to the heterogeneity of the studies included in this
review, we descriptively summarised them.25 We calculated the weighted arithmetic mean of participant age
to consider the number of participants in each study in
relative weighting. In addition, we used a Sankey diagram
to illustrate the relationships between different studies
and study characteristics graphically. In a world map,
we showed the frequencies of the countries in which
the studies were conducted. To summarise and display
descriptively the effects of the interventions on outcomes,
we created a table in which we listed the interventions
in rows and the outcomes in columns. We assigned the
studies to the respective combinations of interventions
and outcomes (numbers shown indicate the respective
3
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study, the colour represents whether the primary outcome
was significant between groups (green), significant within
groups (yellow) and not significant (red)).
RESULTS
In total, 8198 records on non-pharmacological interventions were identified from the databases. After exclusion
of duplicates and title/abstract screening, 226 studies
were analysed in full text. One hundred and nineteen
papers comprising 113 studies (six studies were published
in two articles each29–40) were used for this scoping review.
The PRISMA flow chart of the study selection is depicted
in figure 1. Following the RoB 2,28 4 out of 42 retrieved
RCTs (published in 44 papers) had a low risk of bias, 16
moderate and 22 high (online supplemental file 3). To
provide a comprehensive overview of the various forms
of intervention, we prepared a detailed summary of the
individual study characteristics and interventions (online
supplemental files 4 and 5).
Study characteristics
Participants
In 58 of the 113 studies (51.3%), the participants were
diagnosed with SLE and in 55 (48.7%) with SSc. We
did not find any paper dealing specifically with MCTD
and non-pharmacological interventions. In total, 5140
people were included (n=4687 (91.2%) female, n=332
(6.5%) male, n=121 (2.3%) gender not reported41–46).
However, the authors of one study43 did not report the
number of the patients included. Of the participants,
3484 were diagnosed with SLE (intervention groups (IG)
n=2664 (77.6%), control groups (CG) n=820 (22.4%)),
1632 with SSc (IG n=1055 (66.7%), CG n=577 (33.3%))
and 58 persons were healthy controls. The allocation
of 24 patients diagnosed with SSc in the experimental
group and CG of Freedman et al47 was not reported. The
weighted mean (SD) age of patients with SLE was 42.0
(SD ±6.8) years (weighted mean age IG 42.3 (SD ±6.7);
CG 41.4 (SD ±6.9)) and 54.8 (SD ±4.9) for patients
with SSc (IG 54.3 (SD ±5.1); CG 55.7 (SD ±4.3)). In
seven studies, the authors did not report the participant
age.42 44 48–52
Date and location of publications, study designs
The majority of the studies were published between
2011–2020 (SLE n=36 (31.9%), SSc n=39 (34.5%)) and
2001–2010 (SLE n=16 (14.2%), SSc n=13 (11.5%)).
Forty of all the studies were published in the USA (SLE
n=24 (21.2%), SSc n=16 (14.2%)), 13 in Brazil (SLE n=8
(7.1%), SSc n=5 (4.2%)), 12 in Italy (SLE n=0 (0%),
SSc n=12 (10.6%)), 10 in Canada (SLE n=5 (4.4%), SSc
n=5 (4.4%)) and 8 in the UK (SLE n=3 (2.7%), SSc n=5
(4.4%)) (figure 2). Of the 113 studies, 42 (SLE n=24
(21.2%), SSc n=18 (15.9%)) were RCTs, 20 (SLE n=10
(8.8%), SSc n=10 (8.8%)) were one-group pre/post-test
design, 13 (SLE n=7 (6.2%), SSc n=6 (5.3%)) were quasiexperimental studies and 12 (SLE n=2 (1.8%), SSc n=10
(8.8%)) were single-
case studies. These study designs
4

Figure 2 World map evidence representation. This graph
shows the frequency of the countries in which the published
studies were conducted.

and other characteristics are graphically displayed in the
Sankey diagram (figure 3).
Health professionals providing interventions
In 29 (25.7%) of the 113 articles, the interventions were
performed by multidisciplinary teams. The other study
interventions were performed by physiotherapists (SLE
n=6 (5.3%), SSc n=7 (6.2%)), occupational therapists
(SLE n=1 (0.9%), SSc n=5 (4.4%)), nurses (SLE n=4
(3.5%), SSc n=2 (1.8%)) or other health professionals
(n=43 (38.1%)). In nine studies (8.0%), the interventions were performed by patients/peers (eg, peer
counselling). In 16 studies (SLE n=6 (5.3%), SSc n=10
(8.8%)), the authors did not provide clear information
on the profession of the health professionals delivering
the intervention.7 33 46–48 53–63
Interventions, outcomes, effectiveness
In 52 of the 113 studies (SLE n=24 (21.2%), SSc n=28
(24.8%)), the researchers used multiple or multicomponent interventions to treat their patients, and in 61
studies (SLE n=34 (30.1%), SSc n=27 (23.9%)) single
interventions. Of the 61 studies including a single intervention, 33 (SLE n=16 (14.2%), SSc n=17 (15.0%))
included exercises, 11 (SLE n=11 (9.7%), SSc n=0
(0.0%)) coaching/counselling (eg, goal setting, nutrition counselling, peer counselling, physical activity counselling), 5 (SLE n=2 (1.8%), SSc n=3 (2.7%)) education
(eg, self-management strategies, cope with the disease)
and 4 (SLE n=4 (3.5%), SSc n=0 (0%)) cognitive–behavioural interventions. In the 45 studies (39.8%; including
12 RCTs) where the authors did not clearly define a
primary outcome, multiple outcomes and measurements to evaluate the effect of their studies were used
(online supplemental file 4). Of the 113 articles found,
in 68 (60.8%) a primary outcome was defined. The most
frequent primary outcomes were physical function, such
as range of motion or hand functioning (SLE n=1 (0.9%),
SSc n=15 (13.3%)), mouth opening (SLE n=0 (0%), SSc
n=4 (3.5%)), physical capacity (SLE n=2 (1.8%), SSc n=1
(0.9%)), fatigue (SLE n=3 (2.7%), SSc n=0 (0%)) and
self-management (SLE n=1 (0.9%), SSc n=2 (1.8%)). As
the primary outcome is of utmost importance to decide
Ritschl V, et al. RMD Open 2021;7:e001710. doi:10.1136/rmdopen-2021-001710

Connective tissue diseases

Figure 3 Sankey diagram. This diagram illustrates relationships between different studies and study characteristics
graphically. The bars show the study characteristics that were compared between the studies. The grey lines between the bars
are reflecting the congruencies and differences between the different studies. The wider the grey connection lines are, the more
congruency exists. RCT, randomised controlled trial; SLE, systemic lupus erythematosus; SSc, systemic sclerosis.

on the overall result of the study,64 65 we included only
these in further analysis of the results. Of the 68 articles, 38 described studies with CG (RCT n=30 (44.1%),
quasiexperimental designs n=8 (11.8%)). The studies
including a CG and defining a primary outcome are
displayed in tables 1 and 2. In these tables, the heterogeneity between the study interventions, outcomes and
results becomes apparent. In SLE, 10 of the 19 RCTs
(52.6%) showed a significant positive effect. In SSc, it was
7 out of 21 (33.3%). The outcomes were very different
and varied greatly.
Setting and tailoring the intervention to the patient’s needs
In the 113 articles, 98 (86.7%) of the interventions were
either partly (SLE n=5 (4.4%), SSc n=21 (18.6%)) or
completely supervised (SLE n=46 (40.7%), SSc n=26
(23.0%)). Supervised in this context refers to face-to-
face communication or contact. Partly supervised interventions had an initial face-to-face component, or direct
support was provided at the beginning of the treatment.
In the course of treatment, this support was constantly
reduced. Only 15 of the study interventions (SLE n=7
(6.2%), SSc n=8 (7.1%)) were designed and used as full-
distance intervention programmes.38 42 52 66–76
In total, 52 (SLE n=32 (28.3%), SSc n=20 (17.7%)) of
the interventions were tailored to the patient’s needs and
29 (SLE n=16 (14.2%), SSc n=13 (11.5%)) to the patient’s
physical condition/fitness. ‘Tailored to the needs of the
patient’ in this context means that either individual
coaching/counselling as part of the intervention or that
the measures taken were adapted to the patient’s life
situation. ‘Tailored to the patient’s physical condition/
fitness’ were interventions, mainly exercises, that were
adapted to the patient’s personal ability/capacity, but not
to the patient’s life circumstances or preferences. The
interventions in 21 studies (SLE n=3 (2.7%), SSc n=18
Ritschl V, et al. RMD Open 2021;7:e001710. doi:10.1136/rmdopen-2021-001710

(15.9%)) were not tailored. In nine (SLE n=5 (4.4%),
SSc n=4 (3.5%)) studies, the authors did not provide
information on tailoring or individualisation of the interventions. Of the 15 studies where distance intervention
programmes were used, only 4 (26.7%) were tailored to
the patient’s needs, 2 (13.3%) to the patient’s physical
condition/fitness and 8 (53.3%) of the interventions
were not tailored.
DISCUSSION
This scoping review with a descriptive analysis provides
a comprehensive overview of non-
pharmacological
interventions for people diagnosed with SLE and SSc
regarding content, feasibility and potential suitability in
an e-health setting. CTDs impact people’s lives in multifaceted, complex ways. Thus, there is no single non-
pharmacological intervention that can simultaneously
help these patients reduce pain and fatigue, increase
physical function (eg, range of motion, grip strength)
and enhance health-related quality of life and cope with
the disease. Consequently, the use of multicomponent
interventions, regardless of whether in an e-health setting
or not, seems essential and clinically relevant. Education,
counselling and/or exercises were part of most of the
interventions described. In systematic reviews of exercise/physical activity, it has been shown that being more
physically active reduces, for example, fatigue, pain and
depressive symptoms in people with SLE.77
On purpose, we did not exclude papers based on countries (where the studies were conducted) or publication
date to avoid limiting ourselves to intervention types
that are culturally specific or that might have changed
over time. Our results show that the majority of articles
(87.4%) were published between 2000 and 2020. Potential reasons might be the generally increased number
5
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of studies on non-
pharmacological interventions after
2000 and the growing focus on facilitating more active
involvement of patients in managing their healthcare.
Thus, interventions requiring active participation, such
as patient education, instructions for self-management,
physical activity/exercise and advice regarding a healthy
lifestyle, have been created and evaluated for feasibility
and/or effectiveness.
Most of the interventions described in the studies
were either partly or entirely supervised by healthcare
providers and/or patients/peers (n=98 (87%)). Thus,
these interventions’ feasibility and suitability in an
e-health setting are questionable and should be evaluated in further studies. Non-pharmacological interventions are associated with low adherence rates because
they often involve lifestyle modifications and require
changes in behaviour and daily routine habits, which are
challenging to achieve.78 Therefore, interventions that
have been developed in a supervised setting cannot be
transferred to an unsupervised setting without further
validation.78 79 It might be possible that the supervision
per se is an important trigger for the people with CTDs to
adhere to the treatment and, hence, reach a good/better
clinical outcome.
The studies in our review which included tele/e-health
interventions focused mainly on patient education
and information and were not individually tailored to
patients’ needs. In 2021, we would potentially consider
a larger variety of interventions suitable for e-
health,
including supervised non-pharmacological interventions,
such as physical exercises, functional training, activity
pacing advice, etc. We assume that this is partly due to
the fact that the COVID-19 pandemic has substantially
advanced the tools, but also our skills in digital healthcare delivery. However, we need to consider equity and
access to technologies to not exclude certain groups of
people systematically.
People with CTD experience specific clinical manifestations of their disease, and therefore certain limitations in
everyday life. To account for this individuality, the interventions should be tailored to the patient’s needs.80 In
our results, 81 (72%) of the described face-to-face interventions showed such a tailored approach. However, only
7 out of 15 (47%) e-health programmes were tailored,
which indicates a need for development of innovative
tools and strategies to facilitate personalisation of these
interventions. Artificial intelligence applications might
facilitate that e-
health interventions become smart.
For instance, based on some patient’s characteristics or
responses, specific contents might be available or not.
The scoping review methodology allowed us to focus
on the content, feasibility and potential suitability in an
e-health setting. Compared with a classical analysis of
RCTs, the strength of a scoping review is the possibility to
include a heterogeneous body of literature, conveying a
large number and variety of patients with such particular
clinical conditions that would otherwise not be available.
By descriptively mapping the content of the studies, we
8

were able to identify research gaps and bring together
literature from different disciplines, including intervention programmes with emerging evidence.25
The Sankey diagram analysis shows that in most
studies the interventions were partially or fully supervised. Furthermore, it highlights that studies on SSc
and SLE are balanced in numbers, but studies on non-
pharmacological interventions in people with MCTD
are entirely lacking. However, Sankey diagrams do not
present meaningful differentiations or comparisons as
the widths of the connection lines are similar. Consequently, it was difficult to depict the associations between
specific interventions and their outcomes in the diagram.
For this purpose, we used the representation in table
form. In the tables, we directly contrasted outcomes and
types of interventions which is another way to represent
knowledge gaps or research needs visually. For example,
tables 1 and 2 show that exercise as a single intervention
was evaluated in several studies focusing on different
outcomes. Other non-pharmacological programmes and
interventions were assessed in each case with different
outcomes. Because of this heterogeneity, it is difficult
to compare the studies and effects with each other. For
instance, a self-
management programme was assessed
only in relation to quality of life but not in relation to
other outcomes.45 Further research is needed in this area
to make more reliable statements about effectiveness and
efficacy.
However, we acknowledge that our review has certain
limitations. We focused only on SLE, SSc and MCTD.
Furthermore, conclusions on efficacy cannot be made
with a scoping review design. While we used a comprehensive search strategy, we excluded studies that did not
describe or evaluate a specific intervention. The qualitative studies that we found did not evaluate or describe
interventions. They were almost all preliminary studies
focused on developing an intervention. Thus, they were
excluded because they did not meet the inclusion criteria.
CONCLUSION
Our results underscore the complexity of treating people
with non-pharmacological interventions in CTDs such
as SLE and SSc. An interdisciplinary approach tailored
to the patient’s needs is essential to support people with
SLE and SSc holistically and comprehensively. Education,
counselling/coaching and (promoting) exercises/physical activity are important parts of non-pharmacological
interventions in people with SLE and SSc and are also
suitable for e-health interventions.
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